21.51

1.37% 0.29

After Hours: 21.51

Urogen Pharma Ltd (URGN)

Overview News Price History Option Chain Financials Discussions Forecast

Urogen Pharma Ltd stock is traded at $21.51, with a volume of 816.55K. It is up +1.37% in the last 24 hours and up +16.65% over the past month. UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Previous Close:

$21.22

Open:

$21.39

24h Volume:

816.55K

Relative Volume:

1.03

Market Cap:

$1.05B

Revenue:

$109.79M

Net Income/Loss:

$-153.49M

P/E Ratio:

-6.7014

EPS:

-3.2098

Net Cash Flow:

$-172.59M

1W Performance:

+12.62%

1M Performance:

+16.65%

6M Performance:

+24.41%

1Y Performance:

+100.09%

1-Day Range:

$20.65

$21.53

1-Week Range:

$18.70

$22.02

52-Week Range:

$3.42

$30.00

Urogen Pharma Ltd Stock (URGN) Company Profile

Name

Urogen Pharma Ltd

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

972 9 770 7601

Address

9 HA'TA'ASIYA ST, RA'ANANA

Employee

291

Twitter

@UroGenPharma

Next Earnings Date

2025-03-10

Latest SEC Filings

URGN's Discussions on Twitter

Compare URGN vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
URGN Urogen Pharma Ltd	21.51	1.03B	109.79M	-153.49M	-172.59M	-3.2098
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-26	Initiated	Jefferies	Buy
Aug-19-25	Initiated	Piper Sandler	Overweight
Jun-16-25	Upgrade	H.C. Wainwright	Neutral → Buy
May-22-25	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-16-25	Initiated	Scotiabank	Sector Outperform
Feb-19-25	Resumed	Ladenburg Thalmann	Buy
Aug-22-24	Initiated	Guggenheim	Buy
Feb-08-23	Downgrade	Jefferies	Buy → Hold
Apr-27-22	Initiated	Berenberg	Buy
Apr-16-20	Reiterated	H.C. Wainwright	Buy
Apr-13-20	Reiterated	H.C. Wainwright	Buy
Jan-09-20	Initiated	National Securities	Neutral
May-30-19	Initiated	JP Morgan	Neutral
May-29-19	Initiated	Goldman	Neutral
Jan-29-19	Initiated	H.C. Wainwright	Buy
Nov-08-18	Resumed	Jefferies	Buy
Apr-04-18	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-02-18	Initiated	Ladenburg Thalmann	Buy
Nov-15-17	Reiterated	Oppenheimer	Outperform
Nov-15-17	Downgrade	Raymond James	Outperform → Mkt Perform

View All

Urogen Pharma Ltd Stock (URGN) Latest News

Apr 13, 2026

Market Pulse: Is now the right time to enter UroGen Pharma LtdPortfolio Growth Summary & Fast Entry High Yield Tips - baoquankhu1.vn

Apr 13, 2026

Discipline and Rules-Based Execution in URGN Response - Stock Traders Daily

Apr 13, 2026

Apr 12, 2026

UroGen Pharma (URGN) Is Up 14.6% After Phase 3 ENVISION Data And LG-UTUC Outreach Push - Sahm

Apr 12, 2026

Apr 11, 2026

URGN SEC FilingsUrogen Pharma 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 11, 2026

Apr 10, 2026

Jefferies Initiates UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $40 - 富途牛牛

Apr 10, 2026

Apr 09, 2026

UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer - Sahm

Apr 09, 2026

Apr 08, 2026

UroGen Pharma Ltd. Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment Of Patients with Low-Grade Upper Tract Urothelial Cancer - marketscreener.com

Apr 08, 2026

UroGen Launches LG-UTUC Luminaries Initiative Recognizing - GlobeNewswire

Apr 08, 2026

Apr 07, 2026

Trend Report: Will UroGen Pharma Ltd stock benefit from M AEarnings Growth Summary & Low Volatility Stock Suggestions - baoquankhu1.vn

Apr 07, 2026

Bull Bear: What are the risks of holding UroGen Pharma LtdWeekly Profit Summary & Weekly Setup with High ROI Potential - baoquankhu1.vn

Apr 07, 2026

Apr 04, 2026

Trend Recap: Is UroGen Pharma Ltd a cyclical or defensive stock2026 Reactions & Weekly High Conviction Trade Ideas - baoquankhu1.vn

Apr 04, 2026

Apr 03, 2026

Why The UroGen Pharma (URGN) Investment Story Is Shifting As Analysts Hold Fair Value Steady - Yahoo Finance

Apr 03, 2026

Apr 02, 2026

Activity Recap: Will UroGen Pharma Ltd stock benefit from M AMarket Volume Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn

Mar 31, 2026

URGN: D. Boral Capital Maintains Buy Rating with $33 Price Targe - GuruFocus

Mar 31, 2026

Urogen Pharma's (URGN) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat

Mar 31, 2026

Hennion & Walsh Asset Management Inc. Boosts Stock Position in Urogen Pharma $URGN - MarketBeat

Mar 31, 2026

UroGen’s Zusduri shows 72% event-free rate at 24 months By Investing.com - Investing.com South Africa

Mar 31, 2026

Mar 30, 2026

UroGen Pharma (URGN) Announces Positive Phase 3 Trial Results fo - GuruFocus

Mar 30, 2026

UroGen’s Zusduri shows 72% event-free rate at 24 months - Investing.com

Mar 30, 2026

Urogen Pharma Ltd. Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI - marketscreener.com

Mar 30, 2026

Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI - GlobeNewswire

Mar 30, 2026

Mar 29, 2026

URGN PE Ratio & Valuation, Is URGN Overvalued - Intellectia AI

Mar 29, 2026

Urogen Pharma $URGN Shares Acquired by JPMorgan Chase & Co. - MarketBeat

Mar 29, 2026

Mar 28, 2026

Is UroGen Pharma Ltd a cyclical or defensive stockTrade Volume Summary & Accurate Intraday Trading Signals - baoquankhu1.vn

Mar 28, 2026

Mar 26, 2026

SG Americas Securities LLC Purchases 220,264 Shares of Urogen Pharma $URGN - MarketBeat

Mar 26, 2026

Urogen Pharma (NASDAQ:URGN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Mar 26, 2026

Mar 25, 2026

Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ - openPR.com

Mar 25, 2026

Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | CG Oncology, Janssen, Tyra Biosciences, UroGen Pharma - Barchart.com

Mar 25, 2026

Veteran cancer researcher Mark joins Urogen Pharma to drive progress in urologic oncology - Traders Union

Mar 25, 2026

Mar 24, 2026

Forecast Cut: Can UroGen Pharma Ltd keep up with sector leaders2026 Retail Activity & Low Risk High Win Rate Stock Picks - baoquankhu1.vn

Mar 24, 2026

Mar 21, 2026

UroGen Pharma Hits Day High with Strong 7.12% Intraday Surge - Markets Mojo

Mar 21, 2026

Mar 20, 2026

How UroGen Pharma (URGN) Narrative Is Evolving Around Fair Value Risks And Opportunities - Yahoo Finance

Mar 20, 2026

Mar 19, 2026

Live UroGen Pharma Ltd. (URGN) Technical Analysis - Traders Union

Mar 19, 2026